睿知中国医院研究地图
候选清单

正在招募骨肉瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)

ClinicalTrials.gov 上登记的一项骨肉瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心上海市第六人民医院Shanghai Sixth People's Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07596693,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed incurable or metastatic solid tumors that have failed standard treatment, or for which no standard treatment is currently available.

    入选标准第 3 条

  3. Females of childbearing potential have a negative blood pregnancy test within 7 days prior to administration of the study drug (Non-childbearing potential: surgically sterilized or postmenopausal for at least 2 years). In addition, female subjects of childbearing potential must use medically approved contraceptive measures for 12 months after the start of study treatment and have no egg retrieval during this period.

    入选标准第 13 条

    Male subjects are willing to use medically approved contraceptive measures from the time of signing the informed consent form until 12 months after the start of study treatment, and will not donate sperm during this period.

    入选标准第 14 条

    Prior to administration of the study drug, the subject's anti-tumor therapy has not been sufficiently washed out (2 weeks or 5 half-lives, whichever is shorter).

    排除标准第 17 条

  4. ECOG performance status of 0 or 1.

    入选标准第 5 条

    ECOG performance status of 0 or 1.

    入选标准第 11 条

  5. At least one measurable lesion according to RECIST v1.1 criteria.

    入选标准第 15 条

  6. A history of other malignant tumors within 2 years prior to signing the informed consent form, except for non-melanoma skin cancer, some in situ carcinomas (e.g., cervical cancer, bladder cancer, breast cancer), or low-risk prostate cancer.

    排除标准第 1 条

    Patients with HIV infection.

    排除标准第 4 条

    Patients with HIV infection.

    排除标准第 20 条

  7. Women of childbearing age must have a negative urine/blood pregnancy test during the screening period and agree to use contraceptive measures for at least 1 year after administration; male subjects whose partners are of childbearing potential must agree to use effective barrier contraception for at least 1 year after administration.

    入选标准第 8 条

    Females who are pregnant or breastfeeding.

    排除标准第 10 条

    Females who are pregnant or breastfeeding.

    排除标准第 26 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07596693,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily participate in the clinical study; fully understand the study and voluntarily sign the informed consent form; be willing to comply with and able to complete all trial procedures.
  2. Aged 18 to 70 years (inclusive).
  3. Histologically or cytologically confirmed incurable or metastatic solid tumors that have failed standard treatment, or for which no standard treatment is currently available.
  4. Expected survival time > 6 months.
  5. ECOG performance status of 0 or 1.
  6. Sufficient organ function.
  7. Patients whose tumor lesions can be collected and from whom tumor-reactive TCR sequences can be identified may enter the study.
  8. Women of childbearing age must have a negative urine/blood pregnancy test during the screening period and agree to use contraceptive measures for at least 1 year after administration; male subjects whose partners are of childbearing potential must agree to use effective barrier contraception for at least 1 year after administration.
  9. The patient's KXV01 Injection has been successfully prepared.
  10. Expected survival time > 6 months.
  11. ECOG performance status of 0 or 1.
  12. Sufficient organ function.
  13. Females of childbearing potential have a negative blood pregnancy test within 7 days prior to administration of the study drug (Non-childbearing potential: surgically sterilized or postmenopausal for at least 2 years). In addition, female subjects of childbearing potential must use medically approved contraceptive measures for 12 months after the start of study treatment and have no egg retrieval during this period.
  14. Male subjects are willing to use medically approved contraceptive measures from the time of signing the informed consent form until 12 months after the start of study treatment, and will not donate sperm during this period.
  15. At least one measurable lesion according to RECIST v1.1 criteria.
  16. Toxicities and adverse reactions caused by prior therapy should have resolved to Grade ≤ 1 (except for toxicities considered clinically insignificant, such as chemotherapy-induced alopecia).

排除标准:Exclusion Criteria:

  1. A history of other malignant tumors within 2 years prior to signing the informed consent form, except for non-melanoma skin cancer, some in situ carcinomas (e.g., cervical cancer, bladder cancer, breast cancer), or low-risk prostate cancer.
  2. Uncontrolled infectious diseases within 4 weeks prior to signing the informed consent form.
  3. Active hepatitis B or hepatitis C virus infection.
  4. Patients with HIV infection.
  5. Patients with positive Treponema pallidum.
  6. A history of any of the following cardiovascular diseases within the past 6 months: New York Heart Association (NYHA) Class III or IV heart failure, coronary angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant heart diseases.
  7. Tumor lesions invading the heart or major blood vessels.
  8. Abnormal pulmonary function indicated by a ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) < 70% in pulmonary function tests.
  9. A history of clinically significant central nervous system (CNS) disorders, including but not limited to epilepsy, paresis, aphasia, stroke, severe traumatic brain injury, dementia, Parkinson's disease, cerebellar disease, and organic brain syndrome.
  10. Females who are pregnant or breastfeeding.
  11. A history of primary immunodeficiency or autoimmune disease.
  12. Patients whose disease or condition renders them unable to understand, participate in, and/or comply with the study protocol.
  13. Any other disease that the investigator believes would impair the subject's ability to tolerate protocol treatment or significantly increase the risk of complications.
  14. Current or past history of psychoactive substance abuse or dependence.
  15. Subjects whose underlying condition, in the investigator's judgment, may increase the risk of receiving the investigatory drug or confound the interpretation of toxic reactions and adverse events.
  16. Other conditions deemed unsuitable for participation in the study by the investigator.
  17. Prior to administration of the study drug, the subject's anti-tumor therapy has not been sufficiently washed out (2 weeks or 5 half-lives, whichever is shorter).
  18. Uncontrolled infectious diseases within the previous 4 weeks.
  19. Active hepatitis B or hepatitis C virus infection.
  20. Patients with HIV infection.
  21. Patients with positive Treponema pallidum.
  22. Tumor lesions invading the heart or major blood vessels.
  23. A history of clinically significant central nervous system (CNS) disorders, including but not limited to epilepsy, paresis, aphasia, stroke, severe traumatic brain injury, dementia, Parkinson's disease, cerebellar disease, and organic brain syndrome.
  24. Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases.
  25. Use of the restricted drugs or treatments between Screening Period 1 and Screening Period 2 per the protocol.
  26. Females who are pregnant or breastfeeding.
  27. Subjects whose underlying condition, in the investigator's judgment, may increase the risk of receiving the investigatory drug or confound the interpretation of toxic reactions and adverse events.
  28. Receipt of major surgery (excluding diagnostic surgery) between Screening Period 1 and Screening Period 2, or expected to undergo major surgery during the study period. Subjects with planned or ongoing minor surgical procedures (such as venous access placement, etc.) are eligible for enrollment.

引自 ClinicalTrials.gov, NCT07596693, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07596693,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07596693